ALFA Finder| Revenue growth | FY26 revenue ₹66.9cr; H2 revenue up 23% YoY to ₹41.63cr. |
|---|---|
| Margins | Gross margins improved 54% to 59%; H2 EBITDA margin at 26.3%. |
| Demand visibility | Strong recurring revenue at 93% of business; doctor base grew to 6300+. |
| Management confidence | High; aiming for 30% CAGR and Main Board listing within 3 years. |
Growth
FY26 revenue grew 8.6% YoY to ₹66.9cr; PAT increased to ₹6.6cr from ₹6cr. H2 revenue surged 64.4% sequentially.
Outlook
Targeting 30% CAGR and main board listing in 3 years. Launching Xelix clinic platform to reach 50 clinics.
Risks
Business seasonality (H1/H2 split), regulatory delays in product licensing, and high working capital requirements for inventory maintenance.
Earnings Call filed with NSE, NSE: AAKAAR. Summary written with AI assistance from the document.
Aakaar Medical Technologies Ltd: key numbers
- Share price
- ₹72.00
- Market cap
- ₹102.0 Cr
- Revenue (annual)
- ₹66.96 Cr
- Net profit (annual)
- ₹6.64 Cr
- P/E (TTM)
- 15.4×Sector 54.5×
- Promoter holding
- 67.05%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aakaar Medical Technologies Ltd
All →Aakaar Medical Technologies Annual General Meeting
Aakaar Medical Technologies issued a Postal Ballot Notice seeking approval to appoint Mr. Abhash Meswani as Whole-Time Director with ₹50 lakh annual remuneration for five years.
Aakaar Medical Technologies Earnings Call Transcript: Key Takeaways
H1 FY27 revenue of ₹43.72 Cr (+72.64% YoY) and PAT of ₹3.54 Cr versus a prior loss. Margins were deliberately sacrificed for marketing and the distributor transition. Debtor days (219) and cash (₹1.05 Cr) are the key weak spots.
- Call
- Guides 36% growth
Aakaar Medical Technologies H1 FY27 Results: Turns Profitable, Net Profit ₹3.5 Cr
Aakaar Medical Technologies Ltd reported revenue from operations of ₹43.7 Cr (+72.7% YoY) and net profit of ₹3.5 Cr for H1 FY27.
- Key figure
- Net profit ₹3.5 Cr
Aakaar Medical Technologies Investor Presentation: Key Takeaways
H1 FY27 revenue ₹43.72 Cr (+72.6% YoY), EBITDA ₹5.43 Cr (12.42%), PAT ₹3.54 Cr vs prior loss ₹0.78 Cr. Strategy: doctor-led B2B2C distribution, Xelix clinic network, debtor-days reduction.
Aakaar Medical Technologies Board Meeting Date
Aakaar Medical Technologies Limited will hold a board meeting on 30-Oct-2026 to consider unaudited half-yearly financial results and ESOP matters.
Aakaar Medical Technologies Other Announcement
Aakaar Medical Technologies Limited submitted its Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2026. The report confirms total issued capital remains at 1,41,72,816 equity shares.